

Figure 1




Figure 1 (cont.)




Figure 1 (cont.)




Figure 1 (cont.)





Figure 1 (cont.)






Figure 1 (cont.)

Figure 2




Figure 2 (cont.)




Figure 2 (cont.)




Figure 3




Figure 3 (cont.)




Figure 3 (cont.)




Figure 5

Footnotes are shown on the next page

	Screening Phase	Loading Dose	Open-Label Treatment Phase						End of Treatment (EOT) Visit	Follow-up Phase
	Between Days -35 to -14	Day -14	Cycle 1 Day 1 ± 2 days	Cycle 1 Day 3	Cycle 1 Day 7	Cycle 2 Day 1-7 + 7 days	Cycle 2 Day 17 + 3 days	Cycle 2 Day 17 + 3 days	Cycle ≥3 Day 17 + 3 days	30 & 60 days after EOT ± 7 days
Procedures										
Study Drug Administration										
ARGX-110		X		X		X (D3)	X	X (D3)	X	
Azacytidine			X (D 1-7)			X (D 1-7)		X (D 1-7)		
Blood Sample Collection for Pharmacokinetic and Immunogenicity Analyses										
Pharmacokinetics ^{b) d)}		Pre- & 0h, 2h, 24h, D-10	Pre-AZA	Pre-AZA & Post-ARGX (0h, 2h, 24h)	Pre-ARGX & Post-AZA	D3: Pre-AZA & Post-ARGX (0h)	Pre-ARGX & Post- (0h)	D3: Pre-AZA & Post-ARGX (0h)	Pre-ARGX & Post- (0h)	X
Immunogenicity/ADA ^{c) d)}		Pre-	Pre-AZA	Pre-AZA	Pre-ARGX	D3: Pre-AZA	Pre-	D3: Pre-AZA	Pre-	X
Blood Sample Collection for Disease Evaluation and Biomarkers										
Molecular Genetics ^{d)}		Pre-	Pre-			D1, Pre-		C _{odd} D1, Pre-		X
Gene expression ^{e)}		Pre-	Pre-			D1, Pre-		C _{odd} D1, Pre-		X
Flow cytometry ^{f)}		Pre-	Pre-			D1, Pre-		C _{odd} D1, Pre- _{g)}		
Serum protein quantification ^{g)}		Pre-	Pre-			D1, Pre-		C _{odd} D1, Pre-		X
Stemness determination ^{h)}	X		Pre-						X	
Bone Marrow (BM) Collection for Pharmacokinetics, Immunogenicity, and Disease Evaluation and Biomarkers										
	Between Days -35 to -14	Day -14	Response assessment, monotherapy (C1D1 pre-AZA) ^{k)}			Response assessments, combo treatment ^{l)} (C _{odd} D1, every odd cycle D1 until CR/CRi, pre-AZA)			Within 7 days of EOT ^{a)}	30 & 60 days after EOT ± 7 days
Bone marrow aspirate/biopsy ^{l)}	X		X			C _{odd} D1, pre			X	
Molecular Genetics ^{d)}	X		X			C _{odd} D1, pre			X	
Gene expression ^{e)}	X		X			C _{odd} D1, pre			X	
Flow cytometry ^{f)}	X		X			C _{odd} D1, pre			X	
Stemness determination ^{h)}	X		X			C _{odd} D1, pre			X	
Pharmacokinetics ^{b)}	X		X			C _{odd} D1, pre			X	
Immunogenicity/ADA ^{b)}	X		X			C _{odd} D1, pre			X	

Figure 6




Figure 7





Figure 8

A



B




Figure 9




Figure 9 (continued)

f)




Figure 10




Figure 11

